Open AccessDiffuse alveolar hemorrhage after infliximab treatment of Crohn's disease
Author(s) -
Panagi Sofia,
Palka Wojciech,
Korelitz Burton I.,
Taskin Metin,
Lessnau Klaus D.
Publication year - 2004
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1097/00054725-200405000-00016
Subject(s) - infliximab , medicine , tumor necrosis factor alpha , monoclonal antibody , crohn's disease , adverse effect , inflammatory bowel disease , gastroenterology , disease , monoclonal , necrosis , antibody , immunology
Infliximab (Remicade), a chimeric monoclonal antibody to tumor necrosis factor‐alpha (anti–TNF‐α), is being used with increasing frequency in the treatment of Crohn's disease. Infliximab's safety profile to date has been good with reported adverse events being mild to moderate. We report a case of diffuse alveolar hemorrhage after the second infliximab infusion in a patient with Crohn's disease. The mechanism by which infliximab may have caused the observed pulmonary insult remains unknown. Physicians should be aware of the possible association between infliximab treatment and the development of alveolar hemorrhage. Future cases should be reported.